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Donor specific antibodies after
transplantation
The functions of most organ systems can be
measured precisely, and individuals in a popula-
tion can be ranked according to function. In
striking contrast, the functions of the immune
system cannot be measured precisely nor can one
rank the immunologic fitness of individuals in a
population. The inability to measure immune
function has the greatest impact on children who
undergo transplantation. Such children are trea-
ted with regimens of immunosuppression that
impair growth, vitality, and resistance to infec-
tion and would derive the greatest benefit if the
regimen could be adjusted to suit their needs.
Recently devised technologies and older technol-
ogies newly interpreted for detecting and mea-
suring donor-specific antibodies in those
awaiting transplantation might be adapted to fill
that void if the technologies so applied after
transplantation truly represent the level of
immunity to, and predict the outcome of, the
graft.
The detection prior to transplantation of
antibodies specific for a potential transplant
donor has proven invaluable. High levels of
these antibodies, especially complement-fixing
antibodies, in a potential recipient presage
hyperacute rejection (1); low levels may antici-
pate antibody-mediated rejection (2). We previ-
ously explored in detail how those antibodies
might inflict injury on organ transplants (3, 4)
and will not comment here on this subject.
Basic scientists, such as us, also find the
de novo development of donor-specific antibodies
after the transplantation of interest. From our
perspective, the interest and importance of
donor-specific antibodies arising after transplan-
tation stems from basic and practical questions
about the assays used and the meaning of
positive and negative results. We shall discuss
some of those questions in this communication.
As we are not engaged in clinical practice, we
realize our remarks may betray some naiveté. We
hope readers will take that to indicate a need to
communicate the results of clinical observations
to the broader scientific community.
Are donor-specific antibodies a sensetive index of
immunity?
We first would ask whether donor-specific anti-
bodies are a sensitive index of immunity to
transplantation. Certainly, in the experimental
setting, antibodies to major histocompatibility
antigens are sensitive, specific, and reliable, as
these antibodies allowed the discovery and
mapping of the major histocompatibility locus
(5, 6). We are concerned, however, that after
organ transplantation one might find that some
histocompatibility antigens do not incite humor-
al immunity, at least not continuously, or that
antibodies produced against some antigens might
be absorbed to the graft and hence are scarcely
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detectable or not detectable at all. Unfortunately,
with a graft in place, we think distinguishing the
absence of response on the one hand from
absorption of responding antibodies on the other
based on antibody levels in the blood is difficult
or impossible. The clinical experience that second
transplants with a negative cross-match are at
greater risk than first transplants suggests that
sensitization occurs regardless of whether donor-
specific antibodies are produced. However, the
greater risk might reflect variations in immune
fitness or responsiveness among individuals in a
population rather than sensitization per se. Con-
sistent with the later explanation (variations in
capacity to mount any immune response rather
than prior exposure to a given antigen), Farney
et al. (7) showed that outcome of second trans-
plants sharing HLA antigens with first trans-
plants is no different than the outcome of second
transplants with entirely different HLA types.
Regardless of whether all or only some HLA
mismatches provoke immunity, experimental
kidney transplants, especially, appear capable
of absorbing large amounts of donor-specific
antibodies, leaving little or no detectable anti-
graft antibody in the blood. We can offer
examples from experimental transplants between
species that represent the extreme of humoral
responses to transplantation (4). Fig. 1 shows the
results of one experiment that we have repeated
in many systems (8). A kidney of a squirrel
monkey, which expresses Gala1-3Gal, is perfused
by the blood of a baboon, which does not express
that sugar and makes large amounts of antibody
against it [anti-Gala1-3Gal antibodies represent
1–2% of immunoglobulin in the blood (9)].
Perfusion of the kidney for only one half hour
removes more than 90% of anti-Gala1-3Gal
antibody and indeed of all xenoreactive antibody
from the blood of the baboon. Fig. 2 shows
another experiment in which the heart of a
pig expressing human complement regulatory
proteins is transplanted into a baboon. Rejection
of the heart can be shown to be caused by
(a) (b)
Fig. 2. Concentration of xenoreactive IgM (a) and IgG (b) in baboons after xenotransplantation. Xenoreactive IgG was
measured by ELISA after transplantation of swine hearts into baboons. In each of six baboons, xenoreactive IgG levels
remained at baseline until day 10–15 when the xenografts were removed. Impaired contractility and severe antibody-mediated
rejection were observed by day 7 (arrow). Adapted from Figure 3, McCurry et al. (28), copyright 1997, with permission from
Elsevier.
(a) (b)
Fig. 1. Absorption of xenoreactive and anti-Gala1-3Gal antibodies during perfusion of xenogeneic kidneys. Absorption of
total xenoreactive (a) and anti-Gala1-3Gal antibodies (b) from baboon blood during perfusion of xenogeneic organs. Squirrel
monkey kidneys were connected through ex vivo circuits with the circulation of baboons, and blood was sampled before and
after passage through the kidneys. Total xenoreactive and anti-Gala1-3Gal antibodies were measured by ELISA on the basis
of binding to cultured porcine endothelial cells. Adapted from Figure 3, Collins et al. (8), copyright 1995, The American
Association of Immunologists, Inc.
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anti-Gala1-3Gal antibodies, as removal of those
antibodies prevents rejection (10, 11). In this
experiment, no anti-Gala1-3Gal antibody
appears in the blood until the organ is rejected
and removed from the baboon.
In these models at least, hearts and kidneys
can be shown to remove all or nearly all donor-
specific antibody. Whether kidneys or other
organs can remove all or nearly all anti-HLA
antibodies is not known. As some HLA antigens
are expressed at relatively low levels, it is possible
that quantitative removal of antibodies against
those antigens might not occur. But then, one
would rightly question whether the antigen
density suffices to serve as a target for a patho-
logically significant response.
Is the appearance of donor-specific antibodies in the
blood an early or late sign of humoral immunity to a
graft?
If antibody-mediated rejection is mediated by
antibodies, then obviously those antibodies must
be produced before rejection occurs. Moreover,
as the presence of donor-specific antibodies in the
blood of transplant recipients correlates with
antibody-mediated rejection, one might expect
that the antibodies detected were produced some
finite time before tissue injury occurs and that
those antibodies cause rejection. However, we
question some of these obvious points and think
substantiation is warranted.
If donor-specific antibodies can be absorbed in
large measure by an organ transplant, then tissue
injury and rejection might occur in subjects in
whom donor-specific antibodies are undetectable
in the blood. Further, as the absorption of
antibodies by an organ depends on blood flow
to the organ, the presence of donor-specific
antibodies might be first detected or might
dramatically increase only when blood flow
decreases late in the course of rejection. Hence,
donor-specific antibodies might not represent an
early sign of rejection but rather might represent
a relatively late stage of injury and rejection. In
this setting, donor-specific antibodies mark tissue
injury rather than humoral immunity. Fig. 2
depicting the levels of anti-Gala1-3Gal antibod-
ies in the blood of a baboon following trans-
plantation with a swine heart depicts such a
condition. The arrow in the figure denotes the
time when severe antibody-mediated rejection is
detected in a biopsy. At this time, the level of
anti-Gala1-3Gal antibodies has barely increased
above baseline. Only when the rejected organ is
removed do those antibodies substantially exceed
baseline. A similar observation was made years
ago (12), although whether injury and rejection
were caused by cellular or antibody-mediated
injury was not investigated. Still, in these models
as in our models of antibody-mediated rejection,
the transplant must undergo severe injury before
antibodies are detected in the blood.
We think the question of whether donor-
specific antibodies represent an early or late sign
of humoral rejection is of the greatest importance
for evaluation of assays for these antibodies and
for therapeutics. If donor-specific antibodies can
be detected reliably early in the course or even
prior to rejection, then one can soundly test
whether a given intervention prevents or reverses
rejection. And if, as some believe, ‘‘non-compli-
ance’’ with immunosuppressive therapy sparks
many episodes of rejection, then donor-specific
antibodies might provide a useful index of
compliance with treatment and hence suscepti-
bility to rejection. However, if donor-specific
antibodies are not detected until severe tissue
injury ensues, then failure of a given intervention
might reflect the advanced stage of injury at
the time the intervention was tested and any
usefulness of these antibodies as an index of
compliance would be quite limited.
Are donor-specific antibodies donor specific?
While we have little experience with the various
assays used for human donor-specific antibodies,
we can share here some questions that our
experimental work might suggest. One question
we would pose is whether and to what extent the
measured antibodies represent antibodies that
might perturb a graft. If a transplant absorbs
donor-specific antibodies to any extent, the
absorbed antibodies will likely be of higher
affinity and greater pathogenicity than antibodies
remaining in the blood. The biologic properties
of antibodies in the graft might also differ from
those in the blood. For example, we showed that
antibodies that activate complement inefficiently
can potentially block complement-fixing anti-
bodies from binding to cellular targets (13); if one
or another of these fractions bound to the graft,
the remaining antibodies would have the oppo-
site function of the bound antibodies. Such
competition might also influence assays of spec-
ificity. Because binding of an antibody against
one antigen can sterically hinder binding of an
antibody against another antigen, we would
question whether the specificity of donor-specific
antibodies in the blood of transplant recipients
differs from or represents the specificity of
antibodies bound to the graft. This question is
especially important for assays in which antigenic
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targets are segregated on microspheres, because
the microspheres do not permit competition for
binding that occurs on cell surfaces. On cells,
antibodies against one or a few HLA might
occupy the available surface, sterically blocking
the binding of antibodies against other HLA. In
this setting, analysis of the blood would reveal
antibodies against HLA to which antibodies were
not bound in preference to antibodies against
HLA to which antibodies were actually bound.
Do donor-specific antibodies measure immunity or
inflamation?
Antibody production is stimulated by antigen
plus co-stimulation but also by inflammation (14,
15). Where antibody responses are driven by
antigen, one can induce tolerance or at least long-
standing non-responsiveness in antigen-specific
ways as can be performed for immunity to
coagulation factor VIII (16, 17). On the other
hand, where inflammation drives antibody pro-
duction, these approaches might induce immu-
nity or immunodeficiency. As antigen-specific
and antigen-non-specific stimulation induce com-
parable B-cell responses (in vitro) measuring
donor-specific antibodies alone cannot answer
this question.
As interested as we are in knowing whether
donor-specific antibodies are produced after
transplantation, we are equally interested in
knowing whether antibodies against antigens not
carried by the graft are produced after transplan-
tation. If antibodies against other antigens
increase in a given setting, then onemight consider
two further questions: are donor-specific antibod-
ies (anddonor non-specific antibodies) responding
to inflammation and if so do they predict immune
responsiveness in a general sense; and does this
general capacity to mount an immune response
rather than donor specificity confer heightened
risk of rejection and a bad outcome of transplan-
tation? Perhaps in these cases, therapeutics direc-
ted at inflammation and inflammatory agonists
might be found to be of use.
Are donor-specific antibodies always noxious?
Antibodies against a donor, and even antibodies
against other targets, can potentially regulate
immunity and protect against tissue injury (18).
Donor-specific antibodies can cause enhance-
ment of certain grafts including renal allografts
by blocking interaction of donor antigen with
recipient lymphocytes (19). This phenomenon
has been called enhancement because it was first
observed as enhanced lethality of allogeneic
tumor grafts (20). Although the phenomenon of
enhancement is supported by an abundance of
experimental and clinical experience, it has been
largely ignored in recent years, perhaps because
one cannot reliably use the phenomenon in
therapeutics. In contrast to antibody-mediated
tissue injury, which may vary with antibody
levels, enhancement seems to reflect antigen
density more than antibody concentration (18).
To the extent that enhancement reflects blocking
or suppression of cellular immunity, one might
envision using donor-specific antibodies to test
whether absence of rejection in subjects with
detectable antibodies results from such blocking
or suppression.
Antibodies against a donor can also induce
accommodation (21): a condition in which a
graft appears to acquire resistance to humoral
injury. We have reviewed the subject of accom-
modation elsewhere (22, 23) and will not under-
take to do so here. Rather, we would use the
occasion of this communication to stress that the
challenge of detecting donor-specific antibodies
may be key for identifying and better under-
standing the accommodation.
Accommodation differs from tolerance and
enhancement in that it requires an immune
response that is potentially toxic for a graft
(tolerance and enhancement and immunosup-
pression prevent such responses). We have been
concerned that some and possibly many cases of
accommodation are not detected because donor-
specific antibodies are absorbed to the graft as
discussed earlier. This possibility is illustrated in
Figs. 1 and 2. If donor-specific antibodies can
induce accommodation, then one would want to
consider the benefit of that condition vs. the risk
of rejection, testing strategies for depleting those
antibodies, or inhibiting their production. To the
extent that donor-specific antibodies might
induce protection via the target antigen, as some
work suggests (24, 25), the specificity and/or
function of these antibodies is key for determin-
ing whether they cause harm or benefit. Further,
we have postulated that accommodation itself
may not be entirely beneficial and indeed may
potentially explain, and even cause, chronic
rejection (26, 27). In this setting too, a further
understanding of the biology of donor-specific
antibodies might help refine our understanding
of risk and therapeutics.
Concluding remarks
As basic scientists, we are stimulated by the
current interest in applying new technologies for
measuring of donor-specific antibodies in trans-
plantation. We think that work in this area could
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shed light on the development and regulation of
immunity and the impact of immunity on targeted
tissues. These insights might come from thought-
ful analysis of existing information butmost likely
will require laboratory and clinical efforts that
extend beyond the analyses immediately at hand.
Clinical research seems often to be limited by
reliance on correlations (donor-specific antibodies
correlate with antibody-mediated rejection but do
the measured antibodies cause or are they simply
the residua of loss of perfusion?). However, in
clinical transplantation, one can potentially
access the target of immunity (the graft) and the
immune system of the recipient before and after
exposure to antigen and test for the impact of
genes yet to be implicated in the functions of the
immune system. And, when the value of an assay,
such as donor-specific antibodies, is proved, one
can test whether that assay can rank individuals
for immunologic function. Such opportunities are
not to be exploited in experimental systems
because these systems, particularly the inbred
strains of mice, were developed by selection based
on rejection and because the genetic manipu-
lations on which we rely inevitably generate
compensatory phenotypes, which we make every
effort to ignore.
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